Introduction
Primary bronchogenic carcinoma is one of the most common malignant tumors, and the incidence and mortality of lung cancer are on the rise in China. 1 Non-small cell lung cancer (NSCLC) makes up approximately 85% of all lung cancers. The choice of guiding treatment depends on the size, type and accurate staging of tumor, 2 as surgery, RT, chemotherapy, targeted therapy and immunotherapy can be used for the treatment of lung cancer. 3 Relevant studies have pointed out that a possible approach for IIIA-N2 patients might be a multimodality treatment. [4] [5] [6] [7] For these patients, surgical removal of cancerous swelling is the most commonly used method, with 5-year overall survival (OS) rates in the range of 7%-34%. 8 For patients with completely resected IIIA-N2 NSCLC, POCT has become a recognized adjuvant therapy. [9] [10] [11] PORT is also considered as an effective means of treatment. Previous studies have pointed out that positive lymph node and LNR were confirmed to possess a significant guiding role in the prognosis of PORT with resected IIIA-N2 NSCLC. [12] [13] [14] [15] [16] [17] However, no relevant study has focused on the relationship between positive
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shang et al lymph nodes ratio (PLNR) and postoperative radiotherapy (PORT) in IIIA-N2 NSCLC patients. In our study, we retrospectively analyzed 3,134 patients with resected stage IIIA-N2 NSCLC either receiving or not receiving PORT to identify the subgroups who benefit from PORT. This data originated from the SEER database. According to SEER database, we analyzed the relationship between PLNR and PORT on survival time in the patients with resected IIIA-N2 NSCLC.
Patients and methods
Data source
The SEER is a National Cancer Institute program and is a comprehensive source of population-based data in the United States. 18 The SEER database provides detailed information regarding patient demographics, diagnosis, treatment, and survival outcomes. Using the SEER database and based on the American Joint Committee on Cancer criteria, we selected a total of 3,134 patients with pathologically resected stage IIIA-N2 NSCLC between 2004 and 2013 using the SEER*Stat 8.3.5 software. The inclusion criteria for recruiting patients were as follows: complete resection via either lobectomy or pneumonectomy, no treatment before surgery, only one primary tumor, active follow-up, available clinical information. In addition, patients with benign tumor and other ambiguous and unknown information were all excluded.
ethics statement
Our study was constructed in accordance with the Declaration of Helsinki. We received permission to access SEER program research data with the reference number 11561-Nov2016. This study was also approved by the ethics committee of the Shandong Cancer Hospital affiliated with Shandong University. This study did not involve any personal information, and therefore informed patient consent was not required.
statistical analysis
In this study, differences of patient baseline characteristics were analyzed using the chi-squared test. Our main endpoint was OS, which was defined as the time from diagnosis to death due to any reason. Univariate and multivariate Cox regression analyses were applied to assess the prognostic factors on OS for resected IIIA-N2 NSCLC patients receiving PORT. The X-tile model was applied to determine the cutoff values of PLNR and the Kaplan-Meier method was used to calculate OS compared by means of the log-rank test. All statistical analyses were made using Statistical Product and Service Solutions (SPSS) 22.0 software package. All statistical P-values were two-sided and P<0.05 was considered statistically significant.
Results
Patient characteristics
A total of 3,134 patients with resected stage IIIA-N2 NSCLC from the SEER database treated between 2004 and 2013 were included for analysis. Of these, 1,164 patients (37.1%) with pathological stage IIIA-N2 disease received PORT and 1970 patients (62.8%) did not receive PORT. The baseline characteristics of patients are listed in Table 1 . Among patients receiving PORT, all of them were white (100%), with 51.4% patients less than 60 years of age. The PORT group was with 51% female and 49% male patients, and the ratio of patients at Grades I-II and III-IV were 46% and 54%, respectively. The adenocarcinoma was the main pathological pattern in PORT and non-PORT groups (59.4% vs 58.5%) while the proportion of T1, T2 and T3 were 30.1% vs 27.3%, 61.9% vs 65.3% and 8.4% vs 7.4%, respectively, in both groups. Our results showed that patients who received PORT were related to factors of age (P<0.001) and race (P<0.001). There were no significant differences in sex (P=0.522), grade (P=0.149), pathology (P=0.171) and T stage (P=0.141). 
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PlnR and survival
The primary focus of our study was to examine whether the PLNR was associated with PORT in patients with resected pathological IIIA-N2 NSCLC. Cox proportional hazards model was used to assess the prognostic value of baseline characteristics. Table 2 .
Cutoff determination for PLNR count and survival
The cutoff values of PLNR were determined by the X-tile model. Survival curves were measured using the KaplanMeier and compared by long-rank test. The different cutoff values of PLNR on OS including low (PLNR≤20%), medium (20%<PLNR≤40%) and high (PLNR>40%) were produced by X-tile ( Figure 1A-C) . Survival curves revealed that the patients with PLNR≤20% had a better OS (P=0.007) from PORT, as measured by Kaplan-Meier (Figure 2A) . However, the difference on OS was not found between 20%<PLNR≤40% (P=0.944) and PLNR>40% (P=0.091; Figure 2B and C).
Subgroup analysis for OS based on PLNR
Univariate and multivariate Cox regression analyses were further applied to analyze the effect of PORT on OS based on different cutoff points for PLNR. Our results showed that the patients with PLNR≤20% had a better OS (HR=1.328; 95% CI 1.139-1.549; P<0.001) after receiving PORT. However, the OS benefit was not found in patients with 20%<PLNR≤40% and PLNR>40%. Therefore, PORT was an independent prognostic factor only in patients with PLNR≤20%. The subgroup analysis for OS based on different PLNR is listed in Table 3 .
Discussion
The value of PORT for completely resected IIIA-N2 NSCLC is controversial. A PORT meta-analysis conducted in 1998 has shown that PORT had a detrimental effect on survival. 19 Wisnivesky et al demonstrated that PORT was not associated with improved survival for elderly patients with completely resected stage III NSCLC (HR=1.11; 95% CI 0.97-1.27; P>0.05). 20 In contrast, a growing number of more research has supported the use of modern PORT for completely resected stage IIIA-N2 NSCLC. 21, 22 Recently, several studies have suggested that patients with completely resected stage IIIA-N2 NSCLC may be a result of benefits from PORT. [23] [24] [25] [26] Feng et al have demonstrated that PORT was an independent prognostic factor for improved locoreginal free Survival (HR=0.2, 95% CI 0.1-0.5; P=0.001) and improved OS (HR=0.4, 95% CI 0.2-0.7; P=0.001). 27 The Lung Adjuvant Radiotherapy Trial (LungART, NCT00410683), a randomized trial of modern PORT vs no PORT in patients with resected NSCLC, is ongoing. 28 Patients with stage IIIA-pN2 NSCLC are a heterogeneous group and the treatment for these patients should be individualized. 29 Reif et al showed that surgery alone is considered to have a more limited role in the management of stage IIIA patients. 30 However, many patients with locally advanced or metastatic disease lose the opportunity for surgery at the time of diagnosis.
Chemotherapy and RT have become the most important method to treat these patients. Roth 
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PLNR≤20% may be a benefit from PORT treatment strategy using perioperative chemotherapy and surgery was more effective than surgery alone for patients with IIIA-N2 NSCLC. 31 Furthermore, POCT is considered a recognized treatment method for patients with resected IIIA-N2 NSCLC. In spite of this dispute, PORT was also demonstrated as an effective treatment. Feng et al showed that PORT was an independent prognostic factor for improved OS (HR=0.4, 95% CI 0.2-0.7; P=0.001); female sex (HR=0.5, 95% CI 0.3-0.7; P<0.001) and LNR>20% (HR=2.4, 95% CI 1.7-3.3; P<0.001 ) were the other factors for OS. 27 Wang et al demonstrated that in stage IIIA-pN2 NSCLC, the use of PORT demonstrated better survival results than no PORT for patients with positive LNs with n>3, but not for patients with positive LNs with n≤3. 17 Other studies have reported that several clinical and pathological factors, such as the number of pathologically involved lymph node stations, 32, 33 extracapsular extension, 34 lymph node skip status and positive LNR [12] [13] [14] [15] [16] should be considered when evaluating the risks and benefits of PORT. However, so far, there are no relative reports about the relationship between PLNR and PORT in IIIA-N2 NSCLC patients. The aim of this study is to estimate the association between PORT and PLNR for patients with resected pathological stage IIIA-N2 NSCLC.
In the present study, we regard OS as our main endpoint. The outcomes of multivariable analysis have shown that PLNR and the use of PORT were independent impact factors on OS in patients with resected IIIA-N2 NSCLC. We concluded that PLNR≤20% in patients with IIIA-N2 NSCLC may be a benefit from PORT. X-tile model was conducted to determine the optimal cutoff point. 35 Our study demonstrated that 20% and 40% were the proper cutoff PLNR values for OS with PORT patients. We found that the patients with PLNR less than 20% had a better OS rate. The patients with PLNR>20% had no significant difference on OS.
Why patients with a lower tumoral burden would benefit more from PORT with respect to patients with a higher number of pathological mediastinal lymph nodes? One plausible explanation is that a lower PLNR is associated with a better survival for patients with IIIA-N2 NSCLC than higher PLNR. Also, PLNR may reflect the body's immune system and the tumor-host interaction. The value of the PLNR as a predictor of PORT benefits may also be 
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shang et al a result of the interaction between the immune system and RT. 36 Another possible explanation may be that for patients with high PLNR, the toxicity of PORT is far greater than its benefits. In addition, the lower the PLNR, the number of lymph nodes that may be cleared or the number of negative lymph nodes is more. Studies have shown that the more the number of negative lymph nodes is cleaned, the better the prognosis of the patients. [37] [38] [39] [40] Limitations in this study should be noted. First, this was a retrospective study from the SEER database, and not a randomized controlled clinical trial. Second, some other variables, such as smoking history, type of surgery, involved N2 stations and number of positive nodes, affecting the prognosis, were not included in the present study. Additionally, other adjuvant therapies such as chemotherapy, targeted therapy and endocrine therapy were not included in this study. Finally, due to the constraints of the SEER database, we cannot obtain specific information about the dose and segmentation of PORT and the effects of other postoperative treatments. These issues may have some effects on the results, leading to the limitations of the study, which should be explored in future studies.
To the best of our knowledge, this study is the first to demonstrate PLNR as a prognostic factor for patients with IIIA-N2 NSCLC receiving PORT. This study showed that patients with PLNR≤20% can benefit from PORT with improved OS. The results of this study may be of help for clinicians, surgeons and radiotherapists to choose appropriate treatment. This result requires further large-scale prospective clinical study to confirm these recommendations.
